intralymphatic immunotherapy
Upload: chulalongkorn-allergy-and-clinical-immunology-research-group
Post on 07-May-2015
1.322 views
DESCRIPTION
Intralymphatic Immunotherapy Presented by Theerapan Songnuy, MD. July 26, 2013TRANSCRIPT
![Page 1: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/1.jpg)
Intra-lymphatic Immunotherapy ( ILIT)
Theerapan Songnuy M.D.
July 26, 2013
![Page 2: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/2.jpg)
Outlines
• Introduction• Mechanism of ILIT• Animal model of ILIT• Outcomes of ILIT in human study• Conclusion & take home message
![Page 3: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/3.jpg)
Introduction• Allergic rhinitis is a health problem that causes worldwide
disability : social life, sleep, school, and work 1
• Immunotherapy is the only treatment that diminishes
symptoms, improves quality of life, prevents new
sensitizations, and reduces the development of asthma in
patients suffering from allergic rhinitis 2,3
1Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Aller-gic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63:8-160
2 Frew AJ. 25. Immunotherapy of allergic disease. J Allergy Clin Immunol 2003; 111:S712-93 Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific
immunotherapy. Nat Rev Immunol 2006;6:761-71
![Page 4: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/4.jpg)
Introduction
• Subcutaneous immunotherapy ( SCIT) requires numerous
injections and take several years to complete 4
• Adverse events
• Physician-oriented
• High Cost
• Only 5% of allergic patients with insufficient symptom control undergo SCIT 5
4Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen im-munotherapy: a practice parameter third update. J Allergy Clin Immunol 2011;127: S1-55 5 Frew AJ. Allergen immunotherapy. J Allergy Clin Immunol 2010;125:S306-13.
![Page 5: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/5.jpg)
Introduction• Sublingual Immunotherapy (SLIT)
- Efficacy in AR, prevent asthma in AR,
prevent new sensitization
- Better safety profile
- Convenience & ease of administration at home
- Increase adherence
- Cost-efficacy if compared to pharmacological
treatment alone
But
- Not approved in the US
- Long duration of treatmentImmunol Allergy Clin North Am.2011; 31(3): 561-599
![Page 6: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/6.jpg)
Introduction
• When antigens are administered subcutaneously, just only
small fractions of the antigenic epitopes reach the lymph nodes 8
• As immune responses are initiated in secondary lymphoid organs, seems reasonable that the direct administration of antigens into the highly immuno-competent environment of the lymph nodes induces greater immunogenicity 9
8 Martinez-Gomez JM, Johansen P, Erdmann I, Senti G, Crameri R, Kundig TM.Intralymphatic injections as a new administration route for allergen-specific immu-notherapy. Int Arch Allergy Immunol 2009;150:59-65
9 Zinkernagel RM. Localization dose and time of antigens determine immune reac-tivity. Semin Immunol 2000;12:163-71; discussion 257-344
![Page 7: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/7.jpg)
New Direction of Immunotherapy
Intra-Lymphatic Immunotherapy ( ILIT)
![Page 8: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/8.jpg)
Micro-architecture of the lymph node
• Lymph nodes are organized into 3 zones
1. An antigen- sampling zone
- Subcapsular area & medulla
- Rich in APCs
2. B-cell activation zone
- In the cortex, containing B-cell follicles
3. T-cell activation zone
- In the paracortex
Junt T, Scandella E, Ludewig B. Form follows function: lymphoid tissue microarchitecture in
antimicrobial immune defence . Nat Rev Immunol 2008; 8( 10): 764-75.
![Page 9: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/9.jpg)
Picture
Nat Rev Immunol 2008; 8( 10): 764-75.
![Page 10: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/10.jpg)
Nat Rev Immunol 2008; 8( 10): 764-75.
![Page 11: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/11.jpg)
Pathologic mechanism• Animal studies : vaccines can be given in lower
concentrations & reduced number of injections
when administered directly into the lymph node11
• In mice, intra-lymphatic immunization
- Enhanced allergen-specific IgG &T-cell
responses
- Stimulated the production of the TH1-dependent
subclass IgG2a ( improved protection against
allergen-induced anaphylaxis) 8
11 Eur J Immunol 2005;35:568-74
8 Int Arch Allergy Immunol 2009;150:59-65
![Page 12: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/12.jpg)
![Page 13: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/13.jpg)
Aims
• To compare subcutaneous with direct intra-lymphatic administration of allergens in mice as a means for improving efficacy
![Page 14: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/14.jpg)
Methods• Immunization Protocols
- Female CBA mice ( 6-8 wk old; Harlan, Horst, The Netherland)
- Immunized 3 times with 2-wk intervals
- Injection with major bee venom allergen phospholipase A2 ( PLA2; n=5;
Sigma- Aldrich, Buchs, Switzerland)
- Another group use recombinant Fel d1 ( n=4), Fel d1 was cloned into
the Pqe30 expression vector as an N-terminal [ His]6- tag fusion
protein, produced in E. coli & then purified
- Lipopolysaccharide content of Fel d1 was 1.27 ng/mg of protein
- Allergens were mixed with aluminum hydroxide ( Alhydrogel 3%) &
saline 1 hr before use ( 90 ug for ILIT, 450 ug for SCIT)
- Injection volume were 10 ul for ILIT, 50 ul for SCIT
![Page 15: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/15.jpg)
Methods
Mice
ILIT gr
SCIT gr
Poscontrol
Neg control
Cat fur allergen extract intra-
peritoneal6-wkly ( 1 ug)
Sensiti-zed
Mice
Desensitizedwith1 ug Feld1
2 wk later ( 3 doses)
Adapted from
![Page 16: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/16.jpg)
Methods
• Induction of Anaphylaxis
- All 4 groups were challenged 3 wk after last
desensitization
- Using 30 ug of cat fur allergen extract in saline
( 50 ul intra-peritoneally)
- Body temperature was measured before &
30 min after challenge
![Page 17: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/17.jpg)
Methods
• Antibody Measurements
- Process of incubation:
- Plates coated with cat fur allergen extract, PLA2
- Serial dilution of sera
- Biotinylated goat anti-mouse IgG1, IgG2a
- Absorption was read at 405 nm on Model 550
microplate reader
![Page 18: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/18.jpg)
Methods
• Detection of PLA 2-sIgE
- Using 2 ug/ml anti-mouse IgE capture Ab
- An in-house biotinylated PLA 2 at 3 ug/ml,
for binding to mouse serum
• Detection of Fel d1- sIgE
- Using 2 ug/ml anti-mouse IgE capture Ab
- Incubated with serum from immunized mice
- Then rFel d1 0.6 uM was added
- Finally use anti-Fel d1-biotin Ab at 1:1,000
![Page 19: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/19.jpg)
Methods
• Flow Cytometry & Cytokine Secretion Assay
- One wk after injection, spleens were isolated
then single-cell suspension were prepared
- Measure CD4,CD8, CD 44 etc.
- Analysis of cytokines by ELISA ; IL-2, IL-4,
IL-10, IFN- gamma
![Page 20: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/20.jpg)
Methods
• Bio-distribution
- Compare the relative bio-distribution of ILIT & SCIT
- CBA mice were injected with 99MTc pertechnetate-
labelled human Ig ( Technescan R HIG)
- Using 3 MBq /dose IL or SC at inguinal area
- Four animals each were euthanised at 90 min & 17 hr
- Lungs, spleens, livers, inguinal lymph nodes were
dissected , then analyzed in a Cobra II gamma counter
( radioactive count /min)
![Page 21: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/21.jpg)
![Page 22: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/22.jpg)
![Page 23: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/23.jpg)
![Page 24: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/24.jpg)
![Page 25: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/25.jpg)
![Page 26: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/26.jpg)
In Conclusion
• ILIT may represent a promising method to
- Increase the efficacy of SIT
- Reduce the required allergen doses
- Reduce number of injections
- Reduce the risk of adverse events
as compared to SCIT
![Page 27: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/27.jpg)
Proc Natl Acad Sci USA 2008; 105 ( 46): 17908-17912
![Page 28: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/28.jpg)
Aims
• To evaluate the clinical feasibility & safety of
allergen injection directly into lymph nodes
• To compare its efficacy with subcutaneous
immunotherapy
Proc Natl Acad Sci USA 2008; 105 ( 46): 17908-17912
![Page 29: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/29.jpg)
Methods• RCT study• Time : June 2001-March 2005• Place : The University Hopital Zurich, Switzerland• Participants : seasonal rhino-conjunctivitis, allergic asthma
• Inclusion criteria:
- History of rhino-conjunctivitis
- Aged 18-65 y
- Positive SPT to grass pollen
- Springtime AR with SPT positive to tree pollen
( birch, hazel, alder)
- No clinical symptom but SPT positive to cat dander or HDM
Proc Natl Acad Sci USA 2008; 105 ( 46): 17908-17912
![Page 30: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/30.jpg)
Methods
• Exclusion criteria:
- Blood donation or surgery within 30 d
- Use of investigational drug within 90 d
- Pregnancy or nursing
- Mastocytosis
- Significant cardiovascular, hepatic, renal
hematologic, autoimmune or infectious diseases
- History of HT, malignancy, using B blocker, ACE-I
Proc Natl Acad Sci USA 2008; 105 ( 46): 17908-17912
![Page 31: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/31.jpg)
Methods
• Treatment & F/U Procedure:
Group ILIT
- Three 0.1-ml injection with 1,000 standardized
quality unit of aluminum hydroxide-adsorbed
grass pollen extract (Alutard SQ; ALK-Abello)
- Timing : at day 0, 4 wk, 8 wk
- Route: superficial inguinal lymph node under
US guidanceProc Natl Acad Sci USA 2008; 105 ( 46): 17908-17912
![Page 32: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/32.jpg)
Superficial
Inguinal
Lymph
Node
Clinical Radiology 2003; 58(5): 367-371
![Page 33: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/33.jpg)
Methods Group SCIT
- A total of 54 SC injections over 3 y
( cumulative doses of 4,031,540 SQ-U)
- The allergen doses were increased weekly
for 16 wk
- After reaching maintenance dose(100,000 SQ-U)
injections were given monthly
Proc Natl Acad Sci USA 2008; 105 ( 46): 17908-17912
![Page 34: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/34.jpg)
Methods• NPTs
- Adaptation to room temperature for 10 min
- Anterior rhino-scopy was done at base line
- The 50 ul of isotonic test solution was pushed to middle
nose conch using a pipette
- Allergen diluent : 100- 1,000-10,000-100,000 SQ-U aqueous
grass pollen extract ( Aquagen SQ ) in 10-min intervals
- A symptom score ranging from 0-6 points
- Nasal secretion: none = 0, mild =1, severe = 2
- Sneezing : 0-2 = 0, 3-5 =1, >5 = 2
- Remote symptoms : none = 0, lacrimation or pruritus = 1, chemosis,
urticaria, shortness of breath = 2Proc Natl Acad Sci USA 2008; 105 ( 46): 17908-17912
![Page 35: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/35.jpg)
Methods• NPTs
- Scoring greater than 4 defined as the maximal tolerated pollen conc
- If scoring < 4 with conc of 100,000 SQ-U, the maximum tolerated
dose was 1 Million SQ-U
• SPTs
- A 30 ul serially diluted of grass pollen allergens ( Soluprick Alutard-
SQ;ALK-Abello)
- Recording of severity of hay fever, asthma, nasal congestion
nasal itching, sneezing, red eye & dry cough
* Serum sIgE
- By UniCAP for grass-pollen mix & timothy grass
Proc Natl Acad Sci USA 2008; 105 ( 46): 17908-17912
![Page 36: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/36.jpg)
Proc Natl Acad Sci USA 2008; 105 ( 46): 17908-17912
![Page 37: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/37.jpg)
Proc Natl Acad Sci USA 2008; 105 ( 46): 17908-17912
![Page 38: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/38.jpg)
Proc Natl Acad Sci USA 2008; 105 ( 46): 17908-17912
![Page 39: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/39.jpg)
Proc Natl Acad Sci USA 2008; 105 ( 46): 17908-17912
![Page 40: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/40.jpg)
Proc Natl Acad Sci USA 2008; 105 ( 46): 17908-17912
![Page 41: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/41.jpg)
Proc Natl Acad Sci USA 2008; 105 ( 46): 17908-17912
![Page 42: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/42.jpg)
In Conclusion
• Intra-lymphatic Immunotherapy
- Reduce both number & dose of allergen
- Reduce duration of treatment
- Increase safety
- Less painful
- More compliance
![Page 43: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/43.jpg)
Allergy Clin Immunol 2012;129:1290-6.
![Page 44: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/44.jpg)
Aims
• The phase I/IIa trial• To evaluate the safety, immunogenicity & efficacy
of of ILIT with MAT-Fel d1
• Primary efficacy objective :
- Tolerance to cat dander extract in a titrated
NPT• Secondary efficacy objectives:
- Allergen tolerance in IDTs & SPTs &
immunologic parameters Allergy Clin Immunol 2012;129:1290-6.
![Page 45: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/45.jpg)
Methods
• Patients with cat dander allergy• Enrolled during Aug-Sep 2008• At University Hospital Zurich, Switzerland
• Inclusion criteria :
- History of cat dander allergy ( AR, AC)
- Age of 18-65 y
- Positive at least one concentration of cat
dander extract in SPT
- Positive NPTs to Fel d1
- Detection of serum sIgE to Fel d1
Allergy Clin Immunol 2012;129:1290-6
![Page 46: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/46.jpg)
Methods
• Exclusion criteria:
- Serious immunologic diseases
- Serious cardiovascular diseases
- Malignancies
- Chronic infections
- Use of B-blockers
- Uncontrolled & severe asthma
- Pregnancy or nursing
- Severe psychiatric disorders
Allergy Clin Immunol 2012;129:1290-6
![Page 47: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/47.jpg)
Methods
Allergy Clin Immunol 2012;129:1290-6
![Page 48: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/48.jpg)
Methods• Allergen & placebo preparation
- MAT-Fel d1: a recombinant nonglycosylated fusion protein consisting of 291 amino acid
( Strathmann Biotec GmbH & Co KG ; Hamburg, Germany)
- Stored at -80 C
- Both MAT-Fel d1 & placebo were incubated at room temperature with aluminum hydroxide for > 60 min before injection
- Cat dander allergen extract from Stallergenes ( Antony, France)
- Placebo ( saline in alum )
Allergy Clin Immunol 2012;129:1290-6
![Page 49: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/49.jpg)
Methods
• Intra-nodal injection under US guidance
- Superficial inguinal lymph node
- Administration of 100 ul of either MAT-Fel d1
or placebo
- Using a 1-ml hypodermic syringe with
a 25-gauge needle
Allergy Clin Immunol 2012;129:1290-6
![Page 50: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/50.jpg)
Methods
• NPTs
- Baseline evaluation by rhinoscopy &
rhinomanometry
- A 100 ul of allergen solution ( Alyostal;
Stallergenes, Antony, France) was sprayed
into the wider side of the nose
- Symptoms were scored
- The end point : nasal flow reduction > 40 %Allergy Clin Immunol 2012;129:1290-6
![Page 51: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/51.jpg)
Rhino-manometer
From : www.nagelnetwork.com/rhino.htm
![Page 52: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/52.jpg)
Methods
• SPTs
- Serially diluted allergen solutions
- Prick on the volar forearm
- A wheal size of > 7 mm2 defined as positive
• IDTs
- A 1000-fold dilution of SPTs
- A 100 ul was injected by using 0.5 ml syringe
with 26-gauge needle
- Wheal reaction > 6 mm in diameter as positive Allergy Clin Immunol 2012;129:1290-6
![Page 53: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/53.jpg)
Methods• Determination of Ab
- IgE analyzed by ImmunoCAP
- ELISAs to detect cat dander-specific IgG ,IgG1, IgG4
• Cellular antigen stimulation test
- Leukocytes were isolated then mixed in stimulation
buffer containing IL-3
- Then stimulate with rFel d1, MAT-Fel d1, nFel d1
at 37 C for 40 min
- Allergens were tested at 5, 0.5, 0.05 & 0.005 nmol/l Fel d1
- Supernatants were assayed for soluble leukotrieneAllergy Clin Immunol 2012;129:1290-6
![Page 54: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/54.jpg)
Methods
• T-cell analyses
- Allergen-specific T-cell were determined
- By stimulation of 200,000 PBMCs with LPS-free rFel d1
- Supernatants were analyzed for IL-2, IL-4,IL-5, IL10,
IL17 & IFN gamma
• Mini-rhino-conjunctivitis quality-of-life Q
- Assess symptoms during the last week
Clin Exp Allergy 2000; 30: 132-40
![Page 55: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/55.jpg)
Clin Exp Allergy 2000; 30: 132-40
Clin Exp Allergy 2000; 30: 132-40
![Page 56: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/56.jpg)
Allergy Clin Immunol 2012;129:1290-6
![Page 57: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/57.jpg)
Allergy Clin Immunol 2012;129:1290-6
![Page 58: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/58.jpg)
Allergy Clin Immunol 2012;129:1290-6
![Page 59: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/59.jpg)
Allergy Clin Immunol 2012;129:1290-6
![Page 60: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/60.jpg)
Allergy Clin Immunol 2012;129:1290-6
![Page 61: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/61.jpg)
Allergy Clin Immunol 2012;129:1290-6
![Page 62: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/62.jpg)
In Conclusion
• ILIT with MAT-Fel d1 was safe & induced tolerance
to NPT after 3 injections• This yields over SCIT or SLIT in duration of treatment & less
side effects• Limitations :
- Low pt number
- Symptoms were not assessed at baseline• Future challenges:
- Compare ILIT with MAT-Fel d1 VS rFel d1
- Compare SCIT VS ILIT with MAT-Fel d1
![Page 63: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/63.jpg)
Take Home Messages
• Allergic rhinitis, asthma, & prevention of a new sensitization would be successfully treated by AIT
• Intra-lymphatic immunotherapy yields in less side effect, less time, less dose required but more convenient & adherence than SCIT
• But ILIT needs US-guided & physician-administrated• RCT is needed to confirm the cost-effectiveness of
ILIT in the real-world situation before applying in daily practice
![Page 64: Intralymphatic Immunotherapy](https://reader035.vdocuments.us/reader035/viewer/2022081419/554b018fb4c905c12d8b4db2/html5/thumbnails/64.jpg)
Thank You Very Much